Validation of the new Positron Emissions Tomography (PET) Radioligand (+)-[18F]-Flubatine for Imaging of Nicotinic Acetylcholine Receptors (nAChR) in Alzheimer’s Dementia

Phase 1

• Conditions: healthy volunteers; F00; Dementia in Alzheimer disease

• Registration Number: DRKS00005819
• Lead Sponsor: niversität Leipzig

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-04-01
• Study Completion: 2015-11-30
• Results First Posted: 2020-09-16
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

Healthy volunteers:

1. Males/females aged older than or equal to 55 years of age, females must be without childbearing potential (confirmed by either: age = 60; or history of hysterectomy; or hormone analysis in serum: Estradiol = 20 pg/mL and follicle stimulating hormone (FSH) = 40 IU/L, or last spontaneous bleeding at least 2 years prior to the study start)

2. Able to understand the information provided on purpose and conduct of the clinical study

3. Have signed the informed consent to participate in the study

4. No history of any psychiatric or neurological diseases. Clinical Dementia Rating (CDR) score of 0 (zero) and psychometric test results lying within an interval of one standard deviation from the mean value (mean value and standard deviations adjusted for age and education), for all subtests of the test battery applied.

5. Adequate visual and auditory abilities to complete neuropsychological testing, as assessed by the recruiting investigator

6. = 1 year no smoking or passive smoking

AD patients

1. Males/females aged older than or equal to 55 years of age; females must be without childbearing potential (confirmed by either: age = 60; or history of hysterectomy; or hormone analysis in serum: Estradiol = 20 pg/mL and follicle stimulating hormone FSH = 40 IU/L, or last spontaneous bleeding at least 2 years prior to the study start)

2. Capable of understanding the information provided on purpose and conduct of the clinical study and able to give meaningful informed consent by himself / herself

3. Have signed the informed consent to participate in the study

4. Adequate visual and auditory acuity to complete neuropsychological testing, as assessed by the recruiting investigator

5. AD patients, characterized by:
o Progressive cognitive decline with DSM-IV criteria for Dementia
o Probable Alzheimer Disease according to the NINCDS-ADRDA criteria
o Severity of dementia: mild, with a score of 1 on the Clinical Dementia Rating (CDR) and 20-26 on the Mini Mental State Examination (MMSE)

6. = 1 year no smoking or passive smoking

Exclusion Criteria

All subjects:

1. Haematological or biochemical parameters that are outside the normal range and are considered clinically significant by the investigator.

2. History of alcohol or drug abuse/dependence

3. History of major allergic reactions

4. History of epilepsy

5. History of electroconvulsive therapy

6. Any significant disease or unstable medical condition (e.g. unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection)

7. Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the volunteer’s safety

8. Participants in whom magnetic resonance imaging (MRI) is contraindicated.

9. Patient / Volunteer is in custody by order of an authority or a court of law

10. Exclusion periods from other studies or simultaneous participation in other clinical studies

11. Patient / Volunteer has received another investigational drug in the preceding 2 months

12. Previous enrollment in this study

13. Active Smokers

14. Interuption of central acting drugs less than 5 to 10 half lifes is not possible

15. Inadequate collateral circulation of the hand

AD patients:

1. History, physical or imaging findings of other neurological illness apart from AD such as cerebrovascular disease, inflammatory or infectious disease and other degenerative diseases or other types of dementia such as fronto-temporal lobe dementia or Lewy body disease.

Healthy volunteers:

1. Clinical significant abnormal physical examination

2. Evidence of any significant psychiatric or neurological illness from history, clinical or para – clinical findings

3. History, physical or imaging findings of any significant neurological illness such as cerebrovascular disease, inflammatory or infectious disease and other neurodegenerative diseases

4. Previous significant occupational exposure to ionizing radiation or in whom, within the last 10 years, radioactive substances or when ionizing radiation was applied for the purposes of research. (According to § 24 Abs. 1 Nr. 6 StrlSchV / § 28b Abs. 1 Nr. 6 RöV)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Examination of (+)-[18F]-Flubatine as in-vivo marker of brain a4ß2 nicotinic acetylcholine receptor availability in patients with mild Alzheimer’s disease compared to healthy controls and its evaluation for clinical routine. This will be evaluated on the informations gathered through the (+)-[18F]-Flubatine PET investigation.

Secondary Outcome Measures

Name	Time	Method
1. Determination of the pharmacokinetic parameters and exposure to radiation by (+)-[18F]-Flubatine <br><br>2. Determination of safety and tolerability of (+)-[18F]-Flubatine <br><br>3. Development of a kinetic model in order to quantitatively describe regional central a4ß2 nAChR availability in the brain of patients with AD, as well as healthy volunteers <br>